What is the PEG ratio for Veru Inc. (VERU)?

The PEG ratio for VERU stock is N/A.

What is the TTM average PEG ratio for Veru Inc. (VERU)?

The TTM average PEG ratio for VERU stock is 6.72.

What is the 3Y average PEG ratio for Veru Inc. (VERU)?

The 3Y average PEG ratio for VERU stock is 3.95.

Veru (VERU) PEG Ratio: History & Chart

Compare

Veru Inc.(VERU)

Biotechnology · Miami, FL

$2.47-0.08 (-3.14%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

Compare

About Veru Inc.

Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.

Miami, FL

20 employees

www.verupharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mitchell S. Steiner

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Veru Inc. (VERU)	$39.64M	N/A	6.72	3.95	N/A
Metagenomi, Inc. Common Stock (MGX)vs ›	$38.78M	N/A	N/A	N/A	N/A
Harvard Bioscience, Inc. (HBIO)vs ›	$38.61M	N/A	0.32	0.32	0.32
Incannex Healthcare Limited (IXHL)vs ›	$37.93M	N/A	N/A	N/A	N/A
Precipio, Inc. (PRPO)vs ›	$41.83M	N/A	N/A	N/A	N/A
BioStem Technologies, Inc. (BSEM)vs ›	$41.95M	N/A	N/A	N/A	N/A
Filana Therapeutics, Inc. (FLNA)vs ›	$42.26M	N/A	N/A	N/A	N/A
Rapid Micro Biosystems, Inc. (RPID)vs ›	$42.72M	N/A	N/A	N/A	N/A
Nano-X Imaging Ltd. (NNOX)vs ›	$42.83M	N/A	N/A	N/A	N/A
CVRx, Inc. (CVRX)vs ›	$42.99M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Veru Inc. (VERU)

$39.64M

N/A

6.72

3.95

N/A

Metagenomi, Inc. Common Stock (MGX)vs ›

$38.78M

N/A

Harvard Bioscience, Inc. (HBIO)vs ›

$38.61M

N/A

0.32

Incannex Healthcare Limited (IXHL)vs ›

$37.93M

N/A

Precipio, Inc. (PRPO)vs ›

$41.83M

N/A

BioStem Technologies, Inc. (BSEM)vs ›

$41.95M

N/A

Filana Therapeutics, Inc. (FLNA)vs ›

$42.26M

N/A

Rapid Micro Biosystems, Inc. (RPID)vs ›

$42.72M

N/A

Nano-X Imaging Ltd. (NNOX)vs ›

$42.83M

N/A

CVRx, Inc. (CVRX)vs ›

$42.99M

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

DATE	PEG RATIO
2014-12-02	5.16
2014-12-01	5.36
2014-11-28	5.69
2014-11-26	5.88
2014-11-25	5.84
2014-11-24	5.92
2014-11-21	5.65
2014-11-20	5.52
2014-11-19	5.51
2014-11-18	5.65
2014-11-17	5.63
2014-11-14	5.67
2014-11-13	5.76
2014-11-12	5.89
2014-11-11	5.95
2014-11-10	5.96
2014-11-07	6.00
2014-11-06	6.12
2014-11-05	6.14
2014-11-04	6.14
2014-11-03	6.14
2014-10-31	6.11
2014-10-30	6.12
2014-10-29	5.81
2014-10-28	6.02
2014-10-27	5.64
2014-10-24	5.59
2014-10-23	5.49
2014-10-22	5.51
2014-10-21	5.68
2014-10-20	5.80
2014-10-17	5.79
2014-10-16	5.59
2014-10-15	5.63
2014-10-14	5.61
2014-10-13	5.56
2014-10-10	5.35
2014-10-09	5.33
2014-10-08	5.43
2014-10-07	5.21
2014-10-06	5.39
2014-10-03	5.75
2014-10-02	5.89
2014-10-01	4.44
2014-09-30	4.67
2014-09-29	4.80
2014-09-26	4.77
2014-09-25	4.73
2014-09-24	4.92
2014-09-23	4.84
2014-09-22	4.81
2014-09-19	4.99
2014-09-18	5.13
2014-09-17	5.16
2014-09-16	5.17
2014-09-15	5.35
2014-09-12	4.97
2014-09-11	4.89
2014-09-10	4.95
2014-09-09	4.92
2014-09-08	4.92
2014-09-05	4.97
2014-09-04	5.00
2014-09-03	5.03
2014-09-02	5.05
2014-08-29	5.16
2014-08-28	5.09
2014-08-27	5.19
2014-08-26	5.19
2014-08-25	5.15
2014-08-22	5.03
2014-08-21	5.05
2014-08-20	5.11
2014-08-19	5.23
2014-08-18	5.25
2014-08-15	5.28
2014-08-14	5.33
2014-08-13	5.35
2014-08-12	5.37
2014-08-11	5.45
2014-08-08	5.28
2014-08-07	5.28
2014-08-06	5.05
2014-08-05	5.20
2014-08-04	5.33
2014-08-01	5.21
2014-07-31	5.39
2014-07-30	5.71
2014-07-29	5.72
2014-07-28	5.71
2014-07-25	5.75
2014-07-24	5.78
2014-07-23	5.78
2014-07-22	5.79
2014-07-21	5.72
2014-07-18	5.78
2014-07-17	5.62
2014-07-16	5.78
2014-07-15	5.78
2014-07-14	6.60
2014-07-11	7.69
2014-07-10	7.84
2014-07-09	7.83
2014-07-08	7.82
2014-07-07	7.93
2014-07-03	8.00
2014-07-02	8.00
2014-07-01	8.05
2014-06-30	7.60
2014-06-27	7.66
2014-06-26	7.69
2014-06-25	7.71
2014-06-24	7.65
2014-06-23	7.58
2014-06-20	7.57
2014-06-19	7.58
2014-06-18	7.58
2014-06-17	7.65
2014-06-16	7.62
2014-06-13	7.57
2014-06-12	7.83
2014-06-11	7.84
2014-06-10	7.93
2014-06-09	8.01
2014-06-06	7.97
2014-06-05	7.83
2014-06-04	7.65
2014-06-03	7.88
2014-06-02	8.04
2014-05-30	8.11
2014-05-29	8.20
2014-05-28	8.13
2014-05-27	8.20
2014-05-23	8.20
2014-05-22	8.17
2014-05-21	8.23
2014-05-20	8.11
2014-05-19	8.15
2014-05-16	8.13
2014-05-15	8.39
2014-05-14	8.51
2014-05-13	8.70
2014-05-12	9.10
2014-05-09	9.36
2014-05-08	9.39
2014-05-07	9.50
2014-05-06	9.64
2014-05-05	10.01
2014-05-02	10.04
2014-05-01	7.45
2014-04-30	7.76
2014-04-29	7.66
2014-04-28	7.70
2014-04-25	7.78
2014-04-24	7.90
2014-04-23	7.77
2014-04-22	7.84
2014-04-21	7.77
2014-04-17	7.77
2014-04-16	7.76
2014-04-15	7.70
2014-04-14	7.72
2014-04-11	7.61
2014-04-10	7.69
2014-04-09	7.83
2014-04-08	7.81
2014-04-07	7.75
2014-04-04	7.76
2014-04-03	7.90
2014-04-02	7.96
2014-04-01	7.93
2014-03-31	7.96
2014-03-28	7.78
2014-03-27	7.51
2014-03-26	7.41
2014-03-25	7.48
2014-03-24	7.21
2014-03-21	7.20
2014-03-20	7.21
2014-03-19	7.15
2014-03-18	7.09
2014-03-17	6.93
2014-03-14	6.89
2014-03-13	6.87
2014-03-12	7.14
2014-03-11	7.14
2014-03-10	7.22
2014-03-07	7.26
2014-03-06	7.43
2014-03-05	7.28
2014-03-04	7.18
2014-03-03	7.09
2014-02-28	7.09
2014-02-27	7.02
2014-02-26	6.94
2014-02-25	7.00
2014-02-24	7.09
2014-02-21	7.08
2014-02-20	7.10
2014-02-19	7.20
2014-02-18	7.11
2014-02-14	7.06
2014-02-13	7.04
2014-02-12	6.97
2014-02-11	6.92
2014-02-10	7.01
2014-02-07	7.18
2014-02-06	7.24
2014-02-05	7.18
2014-02-04	7.42
2014-02-03	6.52
2014-01-31	6.65
2014-01-30	6.93
2014-01-29	7.00
2014-01-28	7.08
2014-01-27	7.04
2014-01-24	7.10
2014-01-23	7.10
2014-01-22	7.09
2014-01-21	7.08
2014-01-17	7.08
2014-01-16	7.11
2014-01-15	7.11
2014-01-14	7.14
2014-01-13	7.15
2014-01-10	7.09
2014-01-09	7.05
2014-01-08	7.09
2014-01-07	7.24
2014-01-06	7.18
2014-01-03	7.43
2014-01-02	7.39
2013-12-31	7.50
2013-12-30	7.50
2013-12-27	7.53
2013-12-26	7.53
2013-12-24	7.40
2013-12-23	7.43
2013-12-20	7.21
2013-12-19	7.08
2013-12-18	7.24
2013-12-17	6.94
2013-12-16	7.06
2013-12-13	7.06
2013-12-12	7.47
2013-12-11	7.51
2013-12-10	7.61
2013-12-09	7.78
2013-12-06	7.97
2013-12-05	8.06
2013-12-04	8.03
2013-12-03	2.91
2013-12-02	2.88
2013-11-29	3.00
2013-11-27	2.98
2013-11-26	2.98
2013-11-25	2.98
2013-11-22	3.04
2013-11-21	2.99
2013-11-20	2.97

DATE

PEG RATIO

2014-12-02

5.16

2014-12-01

5.36

2014-11-28

5.69

2014-11-26

5.88

2014-11-25

5.84

2014-11-24

5.92

2014-11-21

5.65

2014-11-20

5.52

2014-11-19

5.51

2014-11-18

5.65

2014-11-17

5.63

2014-11-14

5.67

2014-11-13

5.76

2014-11-12

5.89

2014-11-11

5.95

2014-11-10

5.96

2014-11-07

6.00

2014-11-06

6.12

2014-11-05

6.14

2014-11-04

6.14

2014-11-03

6.14

2014-10-31

6.11

2014-10-30

6.12

2014-10-29

5.81

2014-10-28

6.02

2014-10-27

5.64

2014-10-24

5.59

2014-10-23

5.49

2014-10-22

5.51

2014-10-21

5.68

2014-10-20

5.80

2014-10-17

5.79

2014-10-16

5.59

2014-10-15

5.63

2014-10-14

5.61

2014-10-13

5.56

2014-10-10

5.35

2014-10-09

5.33

2014-10-08

5.43

2014-10-07

5.21

2014-10-06

5.39

2014-10-03

5.75

2014-10-02

5.89

2014-10-01

4.44

2014-09-30

4.67

2014-09-29

4.80

2014-09-26

4.77

2014-09-25

4.73

2014-09-24

4.92

2014-09-23

4.84

2014-09-22

4.81

2014-09-19

4.99

2014-09-18

5.13

2014-09-17

5.16

2014-09-16

5.17

2014-09-15

5.35

2014-09-12

4.97

2014-09-11

4.89

2014-09-10

4.95

2014-09-09

4.92

2014-09-08

4.92

2014-09-05

4.97

2014-09-04

5.00

2014-09-03

5.03

2014-09-02

5.05

2014-08-29

5.16

2014-08-28

5.09

2014-08-27

5.19

2014-08-26

5.19

2014-08-25

5.15

2014-08-22

5.03

2014-08-21

5.05

2014-08-20

5.11

2014-08-19

5.23

2014-08-18

5.25

2014-08-15

5.28

2014-08-14

5.33

2014-08-13

5.35

2014-08-12

5.37

2014-08-11

5.45

2014-08-08

5.28

2014-08-07

5.28

2014-08-06

5.05

2014-08-05

5.20

2014-08-04

5.33

2014-08-01

5.21

2014-07-31

5.39

2014-07-30

5.71

2014-07-29

5.72

2014-07-28

5.71

2014-07-25

5.75

2014-07-24

5.78

2014-07-23

5.78

2014-07-22

5.79

2014-07-21

5.72

2014-07-18

5.78

2014-07-17

5.62

2014-07-16

5.78

2014-07-15

5.78

2014-07-14

6.60

2014-07-11

7.69

2014-07-10

7.84

2014-07-09

7.83

2014-07-08

7.82

2014-07-07

7.93

2014-07-03

8.00

2014-07-02

8.00

2014-07-01

8.05

2014-06-30

7.60

2014-06-27

7.66

2014-06-26

7.69

2014-06-25

7.71

2014-06-24

7.65

2014-06-23

7.58

2014-06-20

7.57

2014-06-19

7.58

2014-06-18

7.58

2014-06-17

7.65

2014-06-16

7.62

2014-06-13

7.57

2014-06-12

7.83

2014-06-11

7.84

2014-06-10

7.93

2014-06-09

8.01

2014-06-06

7.97

2014-06-05

7.83

2014-06-04

7.65

2014-06-03

7.88

2014-06-02

8.04

2014-05-30

8.11

2014-05-29

8.20

2014-05-28

8.13

2014-05-27

8.20

2014-05-23

8.20

2014-05-22

8.17

2014-05-21

8.23

2014-05-20

8.11

2014-05-19

8.15

2014-05-16

8.13

2014-05-15

8.39

2014-05-14

8.51

2014-05-13

8.70

2014-05-12

9.10

2014-05-09

9.36

2014-05-08

9.39

2014-05-07

9.50

2014-05-06

9.64

2014-05-05

10.01

2014-05-02

10.04

2014-05-01

7.45

2014-04-30

7.76

2014-04-29

7.66

2014-04-28

7.70

2014-04-25

7.78

2014-04-24

7.90

2014-04-23

7.77

2014-04-22

7.84

2014-04-21

7.77

2014-04-17

7.77

2014-04-16

7.76

2014-04-15

7.70

2014-04-14

7.72

2014-04-11

7.61

2014-04-10

7.69

2014-04-09

7.83

2014-04-08

7.81

2014-04-07

7.75

2014-04-04

7.76

2014-04-03

7.90

2014-04-02

7.96

2014-04-01

7.93

2014-03-31

7.96

2014-03-28

7.78

2014-03-27

7.51

2014-03-26

7.41

2014-03-25

7.48

2014-03-24

7.21

2014-03-21

7.20

2014-03-20

7.21

2014-03-19

7.15

2014-03-18

7.09

2014-03-17

6.93

2014-03-14

6.89

2014-03-13

6.87

2014-03-12

7.14

2014-03-11

7.14

2014-03-10

7.22

2014-03-07

7.26

2014-03-06

7.43

2014-03-05

7.28

2014-03-04

7.18

2014-03-03

7.09

2014-02-28

7.09

2014-02-27

7.02

2014-02-26

6.94

2014-02-25

7.00

2014-02-24

7.09

2014-02-21

7.08

2014-02-20

7.10

2014-02-19

7.20

2014-02-18

7.11

2014-02-14

7.06

2014-02-13

7.04

2014-02-12

6.97

2014-02-11

6.92

2014-02-10

7.01

2014-02-07

7.18

2014-02-06

7.24

2014-02-05

7.18

2014-02-04

7.42

2014-02-03

6.52

2014-01-31

6.65

2014-01-30

6.93

2014-01-29

7.00

2014-01-28

7.08

2014-01-27

7.04

2014-01-24

7.10

2014-01-23

7.10

2014-01-22

7.09

2014-01-21

7.08

2014-01-17

7.08

2014-01-16

7.11

2014-01-15

7.11

2014-01-14

7.14

2014-01-13

7.15

2014-01-10

7.09

2014-01-09

7.05

2014-01-08

7.09

2014-01-07

7.24

2014-01-06

7.18

2014-01-03

7.43

2014-01-02

7.39

2013-12-31

7.50

2013-12-30

7.50

2013-12-27

7.53

2013-12-26

7.53

2013-12-24

7.40

2013-12-23

7.43

2013-12-20

7.21

2013-12-19

7.08

2013-12-18

7.24

2013-12-17

6.94

2013-12-16

7.06

2013-12-13

7.06

2013-12-12

7.47

2013-12-11

7.51

2013-12-10

7.61

2013-12-09

7.78

2013-12-06

7.97

2013-12-05

8.06

2013-12-04

8.03

2013-12-03

2.91

2013-12-02

2.88

2013-11-29

3.00

2013-11-27

2.98

2013-11-26

2.98

2013-11-25

2.98

2013-11-22

3.04

2013-11-21

2.99

2013-11-20

2.97

PEG Ratio: N/A

VERU PEG Ratio Chart

VERU Average PEG Ratio Chart

VERU PEG Ratio Metrics

VERU Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

PEG Ratio FAQ

VERU PEG Ratio History

Related Metrics